State Street Corporation, with 5.59% or 4.36 million shares worth $45.01 million, holds the second-largest percentage of outstanding shares in Anavex Life Sciences Corp. The top two Mutual Funds, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund, hold 5.70% and 2.91% of the outstanding shares, respectively. Anavex Life Sciences Corp.’s shares have shown a negative trend recently, with -1.73% performance at the end of the last trading session. Over the last 30 days, the stock has decreased by -13.99%, and its performance over the past six months has remained below the industry average. Anavex Life Sciences Corp.’s estimated fiscal year 2023 revenue shows a predicted loss of -35.70% this quarter and a decrease of -25.00% in the next quarter. The company’s year-over-year earnings for the past five years showed a negative growth rate of -13.60%.
Anavex Life Sciences Corp. (NASDAQ:AVXL) traded 1.18 million shares in its last trading session, with a beta of 0.79. The stock’s price closed at $9.10, and it showed a negative trend of -1.73% at the end of the trading day.
Weekly Performance
Anavex Life Sciences Corp.’s stock performance over the last five days remained in the red territory, with a -4.51% decrease. However, the stock’s price increased by 6.38% to reach a weekly high of 9.72 on Tuesday, 03/21/23.
30-Day Performance
Over the last 30 days, Anavex Life Sciences Corp. (NASDAQ:AVXL) is down by -13.99%.
Short Interest
The short interest cover period of Anavex Life Sciences Corp. (NASDAQ:AVXL) is 12.43 day(s), and 18.37 million shares have been sold short.
Price Target and Analyst Projections
According to Wall Street analysts, the consensus price target for Anavex Life Sciences Corp. is $43.75. This translates to a 79.2% increase from its current value. The analysts’ projections forecast that AVXL will reach a low of $28.00 and a high of $58.00. To reach the forecasted high, the stock would need to increase by 537.36%, while it would need to decrease by 207.69% to reach the projected low.
Estimates and Forecasts
Anavex Life Sciences Corp.’s share prices have risen by 0.22% over the past six months, which is well below the industry average of 8.80%. Moreover, the company’s estimated fiscal year 2023 revenue shows a predicted loss of -35.70% this quarter and a decrease of -25.00% in the next quarter.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -13.60%.
Dividends
Anavex Life Sciences Corp.’s next quarterly earnings report is expected to be released around May 08 and May 12.
Major Holders
Anavex Life Sciences Corp.’s shares are held by 215 institutions, with Blackrock Inc. being the largest institutional investor. As of September 29, 2022, it held 6.81% of the shares, which is about 5.31 million shares worth $54.84 million. Insiders hold 3.04% of the company’s shares, while 32.16% are in the hands of institutional investors.
Overall, Anavex Life Sciences Corp.’s performance has been lacking compared to other companies in the same industry. While the stock has shown some increase over the past six months, it is still well below the industry average. Additionally, the company’s estimated revenue shows a predicted loss for the current and next quarter.
State Street Corporation holds the second-largest percentage of outstanding shares of Anavex Life Sciences Corp., with 5.59% or 4.36 million shares worth $45.01 million as of Sep 29, 2022. The top two Mutual Funds as of Dec 30, 2022, were SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. The former held 4.45 million shares worth $41.2 million, making up 5.70% of all outstanding shares, while the latter held roughly 2.27 million shares worth around $23.39 million, representing about 2.91% of the total shares outstanding.
Don’t miss interesting posts on Famousbio
